3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
21
Phase NA
10
Phase 2
9
Phase 1/2
9
Phase 4
1
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
18
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Uterine Cervical Neoplasms
35
Ovarian Neoplasms
31
Endometrial Neoplasms
13
Uterine Cervical Dysplasia
10
Papillomavirus Infections
9
Breast Neoplasms
9
Uterine Neoplasms
7
Ovarian Cysts
6
Lung Neoplasms
6
Stomach Neoplasms
4
Neoplasms
4
Esophageal Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Polycystic Ovary Syndrome
3
Ovarian Hyperstimulation Syndrome
3
Liver Neoplasms
3
Leiomyoma
3
Head and Neck Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Vomiting
2
Uterine Diseases
2
Urinary Bladder Neoplasms
2
Tobacco Use Disorder
2
Squamous Intraepithelial Lesions
2
Small Cell Lung Carcinoma
2
Recurrence
2
Peritoneal Neoplasms
2
Pancreatic Neoplasms
2
Interventions
pazopanib
1
palbociclib
1
olaparib
1
lenvatinib
1
Sunitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Thyroid Neoplasms
×
Gynecologic
×
Clear all
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled